Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 133

1.

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1270. doi: 10.1074/mcp.W119.001571. No abstract available.

PMID:
31154440
2.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Straten PT, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. doi: 10.1074/mcp.RA119.001524.

PMID:
31154438
3.

De sérieuses préoccupations qui ne cachent pas nos espoirs.

Aapro M, Peters S, Dietrich PY.

Rev Med Suisse. 2019 May 15;15(651):999-1000. French. No abstract available.

PMID:
31091031
4.

Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients.

Boydell E, Marinari E, Migliorini D, Dietrich PY, Patrikidou A, Dutoit V.

Cancers (Basel). 2019 Apr 2;11(4). pii: E464. doi: 10.3390/cancers11040464.

5.

Peptides as cancer vaccines.

Calvo Tardón M, Allard M, Dutoit V, Dietrich PY, Walker PR.

Curr Opin Pharmacol. 2019 Mar 1;47:20-26. doi: 10.1016/j.coph.2019.01.007. [Epub ahead of print] Review.

PMID:
30831470
6.

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

Migliorini D, Dutoit V, Allard M, Hallez NG, Marinari E, Widmer V, Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N, Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D, Vargas MI, Walker PR, Patrikidou A, Dietrich PY.

Neuro Oncol. 2019 Feb 12. doi: 10.1093/neuonc/noz040. [Epub ahead of print]

PMID:
30753611
7.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
8.

Learning from the past to design better trials in second-line treatment for mesothelioma patients.

Addeo A, Banna GL, Dietrich PY.

Ecancermedicalscience. 2018 Nov 12;12:881. doi: 10.3332/ecancer.2018.881. eCollection 2018.

9.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
10.

Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.

Genoud V, Marinari E, Nikolaev SI, Castle JC, Bukur V, Dietrich PY, Okada H, Walker PR.

Oncoimmunology. 2018 Sep 5;7(12):e1501137. doi: 10.1080/2162402X.2018.1501137. eCollection 2018.

PMID:
30524896
11.

Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point.

Addeo A, Caparrotti F, Picardi C, Dietrich PY.

J Clin Oncol. 2018 Oct 22:JCO1800461. doi: 10.1200/JCO.18.00461. [Epub ahead of print] No abstract available.

PMID:
30346903
12.

Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy.

Espeli V, Vergotte S, Dietrich PY, Pichard C, Siano M.

Nutr Cancer. 2018 Oct;70(7):1069-1074. doi: 10.1080/01635581.2018.1497670. Epub 2018 Oct 1.

PMID:
30273007
13.

Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors.

Elias KM, Tsantoulis P, Tille JC, Vitonis A, Doyle LA, Hornick JL, Kaya G, Barnes L, Cramer DW, Puppa G, Stuckelberger S, Hooda J, Dietrich PY, Goggins M, Kerr CL, Birrer M, Hirsch MS, Drapkin R, Labidi-Galy SI.

J Pathol. 2018 Dec;246(4):459-469. doi: 10.1002/path.5161. Epub 2018 Oct 19.

PMID:
30229909
14.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Nov;17(11):2132-2145. doi: 10.1074/mcp.RA118.000792. Epub 2018 Aug 2. Retraction in: Mol Cell Proteomics. 2019 Jun;18(6):1270.

PMID:
30072578
15.

Diagnosis and treatment of follicular lymphoma: an update.

Bargetzi M, Baumann R, Cogliatti S, Dietrich PY, Duchosal M, Goede J, Hitz F, Konermann C, Lohri A, Mey U, Novak U, Papachristofilou A, Stenner F, Taverna C, Zander T, Renner C.

Swiss Med Wkly. 2018 Jul 24;148:w14635. doi: 10.4414/smw.2018.14635. eCollection 2018. Review.

16.

[« Doctor, I am fasting during chemotherapy » : illusion or new clinical facts ?]

Frigeri M, Brnic-Bontognali M, Galetti V, Dietrich PY, Bodmer A.

Rev Med Suisse. 2018 May 16;14(607):1034-1036. French.

PMID:
29767895
17.

De vrais espoirs et de sérieuses préoccupations.

Peters S, Dietrich PY, Aapro M.

Rev Med Suisse. 2018 May 16;14(607):1011-1012. French. No abstract available.

PMID:
29767891
18.

[Cancer and sexual medicine: a hand to the human].

Amram ML, Dietrich PY, Rochon F, Bolmont M, Bianchi-Demicheli F.

Rev Med Suisse. 2018 Mar 14;14(598):582-584. French.

PMID:
29537747
19.

[The care of the sexuality among oncologic patients - A research project within the University hospitals of Geneva].

Bolmont M, Amram ML, Rochon F, Dietrich PY, Bianchi-Demicheli F.

Rev Med Suisse. 2018 Mar 14;14(598):578-581. French.

PMID:
29537746
20.

Onco-sexologie : un regard au cœur des patients.

Bianchi-Demicheli F, Dietrich PY.

Rev Med Suisse. 2018 Mar 14;14(598):555-556. French. No abstract available.

PMID:
29537741

Supplemental Content

Loading ...
Support Center